Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D32XRQ
|
|||
| Drug Name |
BAY 853934
|
|||
| Synonyms |
Molidustat; 1154028-82-6; BAY 85-3934; Molidustat (BAY85-3934); BAY85-3934; UNII-9JH486CZ13; Molidustat(BAY 85-3934); 9JH486CZ13; 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)-1H-pyrazol-3-one; 3H-Pyrazol-3-one, 1,2-dihydro-2-[6-(4-morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-; 2-(6-Morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-3(2H)-one; 2-[6-(4-Morpholinyl)-4-pyrimidinyl]-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(1,2,3-triazol-1-yl)pyrazol-3-ol; 2-(6-Morpholin-4-Ylpyrimidin-4-Yl)-4-(1,2,3-Triazol-1-Yl)-1~{h}-Pyrazol-3-One; Molidustat [INN]; Molidustat(BAY85-3934); Molidustat (BAY 85-3934); QEQ; GTPL8456; SCHEMBL2569970; SCHEMBL6114312; CHEMBL3646118; CHEMBL3991036; DTXSID80151089; EX-A562; BDBM118339; AOB87194; BCP14477; MFCD28411428; AKOS026750584; ZINC167006010; BAY-853934; CCG-267626; SB17156; NCGC00388364-04; AK323698; AS-74456; HY-12654; QC-11791; DB-092822; B5861; S8138; A14404; BAY 85-3934;BAY-85-3934; US8653111, 72; Q27087553; OC1=C(N2N=NC=C2)C=NN1C(N=CN=1)=CC=1N1CCOCC1; 1-(6-morpholinopyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-ol; Molidustat;BAY 85-3934;BAY-85-3934; BAY 853934; BAY-853934; BAY853934; 2-(6-(Morpholin-4-yl)pyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-(6-Morpholin-4-ylpyrimidin-4-yl)-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one; 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-2,3-dihydro-1H-pyrazol-3-one; A1H
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anaemia [ICD-11: 3A90; ICD-10: D64.8] | Phase 3 | [1] | |
| Company |
Bayer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H14N8O2
|
|||
| Canonical SMILES |
C1COCCN1C2=NC=NC(=C2)N3C(=O)C(=CN3)N4C=CN=N4
|
|||
| InChI |
1S/C13H14N8O2/c22-13-10(20-2-1-16-18-20)8-17-21(13)12-7-11(14-9-15-12)19-3-5-23-6-4-19/h1-2,7-9,17H,3-6H2
|
|||
| InChIKey |
IJMBOKOTALXLKS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1154028-82-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HIF-prolyl hydroxylase (HPH) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03418168) A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects (MIYABI PD). U.S. National Institutes of Health. | |||
| REF 2 | Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem. 2018 May 23;13(10):988-1003. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.